

Amendments to the Claims:

This listing of claims will replace all prior versions of claims.

1.- 17. (Cancelled)

18. (Previously Presented) An isolated polypeptide encoded by the polynucleotide sequence consisting of SEQ ID NO:1.

19.-21. (Cancelled)

22. (Currently Amended) The isolated polypeptide according to claim 39 ~~24~~, which has angiogenesis activity.

23. (Currently Amended) The isolated polypeptide according to claim 39 ~~24~~, which has vascular endothelial cell growth activity.

24. (Currently Amended) A pharmaceutical composition for angiogenesis, which comprises the polypeptide of claim 39 ~~24~~.

25. (Previously Presented) A pharmaceutical composition for growth of vascular endothelial cells, which comprises the polypeptide of claim 18.

26. (Previously Presented) A pharmaceutical composition for the treatment of a disease selected from the group consisting of occlusive arterial disease, arteriosclerosis obliterans, Buerger disease, angina, myocardial infarction, cerebral infarction, ischemic heart disease, and ischemic cerebral disease, which comprises the polypeptide of claim 18.

27.-38. (Cancelled)

39. (Previously Presented) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

40. (Previously Presented) A pharmaceutical composition for growth of vascular endothelial cells, which comprises the polypeptide of claim 39.

41. (Previously Presented) A pharmaceutical composition for the treatment of a disease selected from the group consisting of occlusive arterial disease, arteriosclerosis obliterans, Buerger disease, angina, myocardial infarction, cerebral infarction, ischemic heart disease, and ischemic cerebral disease, which comprises the polypeptide of claim 39.

42.-46. (Cancelled)